Evan Sengbusch is CEO of Archeus Technologies, a Madison-based biotechnology company developing a portfolio of radiopharmaceutical therapies in oncology. Since the start of his tenure with Archeus, he has translated the its lead assets from preclinical phase into human clinical trials with three investigational new drug approvals from FDA and 2 phase one clinical trials opened, in addition to expanding its early stage drug pipeline. Prior to Archeus, Evan was President of Phoenix, a developer and manufacturer of particle accelerator technologies with applications in nuclear medicine, energy, and defense. Over the course of a decade, he led Phoenix’s growth to >120 employees across multiple locations and ~$20M in annual revenue. Phoenix was acquired by SHINE Technologies in 2021, after which Evan served as General Manager of the Phoenix Division and then Chief Business Development Officer of SHINE.
Evan has MS and Ph.D. degrees in Medical Physics from UW-Madison and is a UW Weinert Center for Entrepreneurship MBA graduate from the Strategic Management in the Life and Engineering Sciences program. Throughout his career he has focused on transitioning new technologies from the lab into commercial and clinical use and has led several successful equity financings totaling >$50M, as well as a successful company exit transaction.
In addition to his role at Archeus, Evan also serves on the board of directors of RPT Labworks, a preclinical CRO focused on radiopharmaceutical drug development, and the board of the Green Lake Association, a non-profit focused on protecting and improving water quality on Green Lake, WI, where he and his family of four spend much of their summer time as avid watersports enthusiasts.